Highlights of a workshop to discuss targeting inflammation in cystic fibrosis

被引:21
作者
Banner, Katharine H. [1 ]
De Jonge, Hugo [2 ]
Elborn, Stuart [3 ]
Growcott, Ellena [1 ]
Gulbins, Erich [4 ]
Konstan, Mike [5 ]
Moss, Rick [6 ]
Poll, Chris [1 ]
Randell, Scott H. [7 ]
Rossi, Adriano G. [8 ]
Thomas, Lorraine [1 ]
Waltz, David [9 ]
机构
[1] Novartis Inst Biomed Res, Horsham RH12 5AB, W Sussex, England
[2] Erasmus Univ, Med Ctr, Dept Biochem, NL-3000 CA Rotterdam, Netherlands
[3] Belfast City Hosp, Adult Cyst Fibrosis Ctr, Belfast BT9 7AB, Antrim, North Ireland
[4] Univ Duisburg Essen, Dept Mol Biol, D-45122 Essen, Germany
[5] Case Western Reserve Univ, Rainbow Babies & Childrens Hosp, Div Pediat Pulmonol, Cleveland, OH 44106 USA
[6] Stanford Univ, Sch Med, Dept Pediat, Div Allergy & Immunol, Palo Alto, CA 94304 USA
[7] Univ N Carolina, Sch Med, Cyst Fibrosis Pulm Res & Treatment Ctr, Chapel Hill, NC 27599 USA
[8] Univ Edinburgh, Sch Med, MRC, Ctr Inflammat Res,Queens Med Res Inst, Edinburgh EH16 4TJ, Midlothian, Scotland
[9] Novartis Inst Biomed Res, Cambridge, MA USA
基金
英国医学研究理事会;
关键词
Cystic fibrosis; Inflamation; Neutrophil; Lymphocyte; Epithelial cell; NF-KAPPA-B; COLONY-STIMULATING FACTOR; AIRWAY EPITHELIAL-CELLS; PSEUDOMONAS-AERUGINOSA; LUNG-DISEASE; CYTOKINE PRODUCTION; PULMONARY-FUNCTION; SPUTUM BIOMARKERS; INFECTION; LYMPHOCYTES;
D O I
10.1016/j.jcf.2008.10.002
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
A workshop to discuss anti-inflammatory approaches in the treatment of CF was held at Novartis Institutes for Biomedical Research (NIBR, Horsham, UK) in March 2008. Key opinion leaders in the field (Hugo De Jonge, Stuart Elborn, Erich Gulbins, Mike Konstan, Rick Moss, Scott Randell and Adriano Rossi), and NIBR scientists were brought together to collectively address three main aims: (i) to identify anti-inflammatory targets in CF, (ii) to evaluate the pros and cons of targeting specific cell types and (iii) to discuss model systems to profile potential therapeutic agents. The highlights of the workshop are captured in this review. (c) 2008 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:1 / 8
页数:8
相关论文
共 78 条
[1]   Inflammatory response in airway epithelial cells isolated from patients with cystic fibrosis [J].
Aldallal, N ;
McNaughton, EE ;
Manzel, LJ ;
Richards, AM ;
Zabner, J ;
Ferkol, TW ;
Look, DC .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2002, 166 (09) :1248-1256
[2]   Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework [J].
Atkinson, AJ ;
Colburn, WA ;
DeGruttola, VG ;
DeMets, DL ;
Downing, GJ ;
Hoth, DF ;
Oates, JA ;
Peck, CC ;
Schooley, RT ;
Spilker, BA ;
Woodcock, J ;
Zeger, SL .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2001, 69 (03) :89-95
[3]  
AUERBACH HS, 1985, LANCET, V2, P686
[4]   LYMPHOCYTES-T AND ACTIVATED EOSINOPHILS IN AIRWAY MUCOSA IN FATAL ASTHMA AND CYSTIC-FIBROSIS [J].
AZZAWI, M ;
JOHNSTON, PW ;
MAJUMDAR, S ;
KAY, AB ;
JEFFERY, PK .
AMERICAN REVIEW OF RESPIRATORY DISEASE, 1992, 145 (06) :1477-1482
[5]   The protease-antiprotease battle in the cystic fibrosis lung [J].
Balfour-Lynn, IM .
JOURNAL OF THE ROYAL SOCIETY OF MEDICINE, 1999, 92 :23-30
[6]   Randomised controlled trial of inhaled corticosteroids (fluticasone propionate) in cystic fibrosis [J].
BalfourLynn, IM ;
Klein, NJ ;
Dinwiddie, R .
ARCHIVES OF DISEASE IN CHILDHOOD, 1997, 77 (02) :124-130
[7]  
BETHESDA MD, PATIENT REGISTRY 200
[8]   Multiorgan nuclear factor kappa B activation in a transgenic mouse model of systemic inflammation [J].
Blackwell, TS ;
Yull, FE ;
Chen, CL ;
Venkatakrishnan, A ;
Blackwell, TR ;
Hicks, DJ ;
Lancaster, LH ;
Christman, JW ;
Kerr, LD .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2000, 162 (03) :1095-1101
[9]   Altered respiratory epithelial cell cytokine production in cystic fibrosis [J].
Bonfield, TL ;
Konstan, MW ;
Berger, M .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 1999, 104 (01) :72-78
[10]   Granules of the human neutrophilic polymorphonuclear leukocyte [J].
Borregaard, N ;
Cowland, JB .
BLOOD, 1997, 89 (10) :3503-3521